Looking Forward to the Future of Heparin: New Sources, Developments and Applications
| dc.contributor.author | Fareed, Jawed | * |
| dc.contributor.author | Torri, Giangiacomo | * |
| dc.date.accessioned | 2021-02-11T18:02:35Z | |
| dc.date.available | 2021-02-11T18:02:35Z | |
| dc.date.issued | 2018 | * |
| dc.date.submitted | 2019-08-28 11:21:28 | * |
| dc.identifier | 35956 | * |
| dc.identifier.uri | https://directory.doabooks.org/handle/20.500.12854/51985 | |
| dc.description.abstract | This book is a printed edition of the Special Issue Looking Forward to the Future of Heparin: New Sources, Developments and Applications that was published in Molecules | * |
| dc.language | English | * |
| dc.subject | QD1-999 | * |
| dc.subject | Q1-390 | * |
| dc.subject.classification | thema EDItEUR::P Mathematics and Science::PN Chemistry | en_US |
| dc.subject.other | alginate | * |
| dc.subject.other | n/a | * |
| dc.subject.other | edema | * |
| dc.subject.other | Heparin Red | * |
| dc.subject.other | solid lipid nanoparticles | * |
| dc.subject.other | Fe3O4·DA-BSA/HA | * |
| dc.subject.other | dermatan sulfate | * |
| dc.subject.other | sulfated alginate | * |
| dc.subject.other | porcine heparin | * |
| dc.subject.other | theranostics | * |
| dc.subject.other | low-molecular-weight heparin | * |
| dc.subject.other | Arixtra® | * |
| dc.subject.other | biomaterials | * |
| dc.subject.other | hepcidin | * |
| dc.subject.other | ovarian cancer | * |
| dc.subject.other | iron oxide nanoparticles | * |
| dc.subject.other | heparin-induced thrombocytopenia | * |
| dc.subject.other | bone morphogenetic protein (BMP) | * |
| dc.subject.other | hyaluronic acid (HA) | * |
| dc.subject.other | crude heparin | * |
| dc.subject.other | platelets | * |
| dc.subject.other | resistance | * |
| dc.subject.other | sclerostin | * |
| dc.subject.other | LMWH | * |
| dc.subject.other | gremlin | * |
| dc.subject.other | low molecular weight heparin (LMWH) | * |
| dc.subject.other | low molecular weight glycosaminoglycans | * |
| dc.subject.other | human plasma | * |
| dc.subject.other | single crystal X-ray structure | * |
| dc.subject.other | iron homeostasis | * |
| dc.subject.other | noggin | * |
| dc.subject.other | super paramagnetic iron oxide nanoparticles (SPION) | * |
| dc.subject.other | manufacturing methods | * |
| dc.subject.other | paclitaxel (PTX) | * |
| dc.subject.other | brain injury | * |
| dc.subject.other | bovine heparin | * |
| dc.subject.other | inflammation | * |
| dc.subject.other | qNMR | * |
| dc.subject.other | antithrombin | * |
| dc.subject.other | reference standard | * |
| dc.subject.other | quantitative NMR | * |
| dc.subject.other | enoxaparin | * |
| dc.subject.other | danaparoid sodium | * |
| dc.subject.other | NMR | * |
| dc.subject.other | GDNF | * |
| dc.subject.other | orthogonal multi-analytical methods | * |
| dc.subject.other | ternary complex | * |
| dc.subject.other | heparan sulphate | * |
| dc.subject.other | serglycin | * |
| dc.subject.other | bovine serum albumin (BSA) | * |
| dc.subject.other | HSQC | * |
| dc.subject.other | recombinant expression | * |
| dc.subject.other | heparin | * |
| dc.subject.other | heparin oligosaccharides | * |
| dc.subject.other | functional assay | * |
| dc.subject.other | BMP antagonists | * |
| dc.subject.other | intestinal lymphatic absorption | * |
| dc.subject.other | size exclusion chromatography | * |
| dc.subject.other | heparin coating | * |
| dc.subject.other | diagnosis | * |
| dc.subject.other | bioreactor | * |
| dc.subject.other | anemia | * |
| dc.subject.other | proteoglycan | * |
| dc.subject.other | heparin process | * |
| dc.subject.other | PCA | * |
| dc.subject.other | chemometric | * |
| dc.subject.other | fluorescent probe | * |
| dc.subject.other | pharmacopeia | * |
| dc.subject.other | affinity chromatography | * |
| dc.subject.other | component quantitative analysis | * |
| dc.subject.other | Fondaparinux sodium | * |
| dc.subject.other | perylene diimide dyes | * |
| dc.subject.other | thrombin inhibition | * |
| dc.subject.other | extended physicochemical characterization | * |
| dc.subject.other | cisplatin | * |
| dc.subject.other | glycosaminoglycans | * |
| dc.subject.other | TGF-? | * |
| dc.subject.other | chondroitin sulfate | * |
| dc.subject.other | dalteparin | * |
| dc.subject.other | sequence and compositional investigations | * |
| dc.subject.other | molecular weight | * |
| dc.subject.other | magnetic resonance imaging (MRI) | * |
| dc.subject.other | industrial | * |
| dc.subject.other | LC-MS | * |
| dc.subject.other | iduronic acid conformation | * |
| dc.subject.other | heparan sulfate | * |
| dc.subject.other | growth and differentiation factor (GDF) | * |
| dc.subject.other | assay | * |
| dc.subject.other | subarachnoid hemorrhage | * |
| dc.title | Looking Forward to the Future of Heparin: New Sources, Developments and Applications | * |
| dc.type | book | |
| oapen.identifier.doi | 10.3390/books978-3-03842-950-0 | * |
| oapen.relation.isPublishedBy | 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 | * |
| oapen.relation.isbn | 9783038429500 | * |
| oapen.relation.isbn | 9783038429494 | * |
| oapen.pages | 282 | * |
| oapen.edition | 1st | * |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||

